Tel. : 01 45 33 67 17 / E-mail : coger@coger.fr
AVANTI POLAR LIPIDS , CYGNUS , LARODAN , ADIPOGEN , MYBIOSOURCE , SERVA NORDMARK, BIOWORLD, EDGEBIO , PANREAC APPLICHEM
Ajouter au panier
Le produit a été ajouté au panier Le stock est insuffisant. unités ont été rajoutées au panier Total:
|
Stock épuisé.
En rupture de stock
|
Quantité minimum d'achat
La quantité minimum d'achat n'est pas atteinte
|
photos non contractuelles
Product description: The compound (Akt-I-2) inhibited both Akt1 and Akt2 with IC(50) values of 2.7 and 21 µM respectively. It does not inhibit AKT3. The compound is a reversible inhibitor, and exhibits a linear mixed-type inhibition against ATP and peptide substrate. In addition to inhibiting kinase activity of AKT1 and AKT2 isoforms, AKT-I-1,2 blocked the phosphorylation and activation of AKT1 and AKT2 by PDK1 (phosphoinositide-dependent kinase 1). The inhibitor was found to be cell-active and to block phosphorylation of Akt at Thr308 and Ser473, reduce the levels of active Akt in cells, block the phosphorylation of known Akt substrates and promote TRAIL (tumour-necrosis-factor-related apoptosis-inducing ligand)-induced apoptosis in LNCap prostate cancer cells.
Alternate Names/Synonyms: AktI2
Product Type: Chemical
Molecular Formula: C23H21N3 . HCl
Molecular Weight: 339.4 . 36.5
CAS: 473382-50-2
Purity: >95%
InChiKey: NXSKOEXUDZHMAL-UHFFFAOYSA-N
Appearance Solid.
Solubility: Soluble in DMSO.
Short Term Storage: +4°C
Long Term Storage: -20°C
Shipping: AMBIENT
Use & Stability: Stable for at least 2 years after receipt when stored at -20°C.
Alerte
Veuillez saisir les champs obligatoires! |